PUBLIC COMPANY
save$ATAIAtaiBeckley Inc.
$ATAI7.2400-0.28%New York, NY, USupdated 16h ago
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 20, 26option exerciseCraig Kevin James · Chief Medical Officer27,280 sh
- Apr 20, 26option exerciseCraig Kevin James · Chief Medical Officer15,299 sh
- Apr 20, 26option exerciseCraig Kevin James · Chief Medical Officer15,299 sh
- Apr 20, 26option exerciseCraig Kevin James · Chief Medical Officer27,280 sh
- Apr 8, 26option exerciseAngermayer Christian · 10% owner410,162 sh
- Apr 8, 26option exerciseAngermayer Christian · 10% owner103,000 sh
🐶 Hiring Signal
News
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 25d ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 1mo ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that